A5023235157- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Bone fractures and treatments
- Spine and Intervertebral Disc Pathology
- Liver Disease and Transplantation
- Hip and Femur Fractures
- Orthopedic Surgery and Rehabilitation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Shoulder and Clavicle Injuries
- Shoulder Injury and Treatment
- Total Knee Arthroplasty Outcomes
- Cervical and Thoracic Myelopathy
- Hip disorders and treatments
- Liver physiology and pathology
- HIV/AIDS drug development and treatment
- Urinary Bladder and Prostate Research
- Knee injuries and reconstruction techniques
- Hormonal and reproductive studies
- Neurogenetic and Muscular Disorders Research
- Liver Diseases and Immunity
- Long-Term Effects of COVID-19
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
2021-2025
Hiroshima University
1978-2023
Hiroshima University Hospital
2018-2021
Life Science Institute
2020
Toranomon Hospital
2018
Japan Organization of Occupational Health and Safety
1974-1984
Spinal Injuries Center
1984
Kagoshima University
1984
Yamaguchi University Hospital
1977-1978
Although the effect of levocarnitine (L-carnitine) on hyperammonemia has been reported in patients with liver cirrhosis (LC), its sarcopenia remains to be elucidated. We assessed effects L-carnitine LC. retrospectively evaluated 52 LC who were treated for more than 3 months between February 2013 and June 2017. Computed tomography was used measure cross-sectional area skeletal muscles at level third lumbar vertebra. The relative change muscle index (SMI) per year (ΔSMI/year) computed each...
This study investigated early tumor marker response and treatment in patients with advanced hepatocellular carcinoma (HCC) treated lenvatinib.Twenty HCC who received lenvatinib were enrolled this retrospective study. α-Fetoprotein (AFP) des-γ-carboxyprothrombin (DCP) levels measured before as well 2 4 weeks after treatment. The objective rate was evaluated by mRECIST at 6 weeks.The 30% (complete response/partial response/stable disease/progressive disease: n = 0/6/6/8 cases) mRECIST. At...
The measurement of body composition such as the skeletal muscle index (SMI) has been reported to be useful for predicting prognosis in hepatocellular carcinoma (HCC). In this study, we analyzed change during sorafenib and lenvatinib therapy association between SMI prognosis.A total 67 patients with advanced HCC Child-Pugh grade A status treated tyrosine kinase inhibitors (TKIs) at Hiroshima University September 2009 December 2018 were enrolled retrospective cohort study. Patients underwent...
Abstract Aim We aimed to evaluate the effect of pemafibrate, a selective peroxisome proliferator‐activated receptor‐α modulator, on patients with primary biliary cholangitis (PBC) complicated by dyslipidemia. Methods In total, 61 PBC (Add‐on group: 33 ursodeoxycholic acid [UDCA] + pemafibrate combination therapy; Switch 28 who switched from UDCA other fibrates therapy) were included in study. Changes aspartate aminotransferase (AST), alanine (ALT), gamma‐glutamyl transferase (GGT), alkaline...
Background and Aims: Mutations within the precore (PC) basal core promoter (BCP) regions of HBV genome are associated with fulminant hepatitis reactivation. These mutations may enhance viral replication, but little is known about whether they directly induce damage to liver. We investigated mechanisms direct cytopathic effects induced by infection PC/BCP mutants in absence immune response vitro vivo . Approach Results: Mice humanized livers hepatocytes derived from mice were infected either...
<b><i>Introduction:</i></b> Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC). We analyzed the outcomes of a cohort HCC who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev) as first-line systemic HCC, aim identifying prognostic factors survival. <b><i>Methods:</i></b> total 825 advanced and B Sor, Len Atezo Bev therapy. Liver function was assessed...
We have experienced the five cases of tibial plateau fracture in early half year.Case 1. lateral condylus tibiae and eminentia fracture, 2. completely unstable 3. crush condylus, 4. local 5. split bilateral condylus. Case were achieved with closed method, but after 2 months case was open reduction, bacause its calcification had been poor. performed by reduction internal fixation immediate mobilization knee. only 5 not followed longer than a year, so this report should be considered result...
Abstract We aimed to investigate the early changes in ammonia levels and liver function patients with advanced hepatocellular carcinoma treated lenvatinib. This retrospective study included 23 who were able receive lenvatinib continuously for at least 1 week. compared their (NH3), total bilirubin (Bil), albumin, prothrombin (PT) activity before after week of administration, additionally, 2 groups which divided based on presence/absence portosystemic collaterals (PSCs). Before administration...
Although lenvatinib was recently approved for treatment of advanced unresectable hepatocellular carcinoma (HCC) based on the phase III REFLECT trial, no biomarkers management have been established. The aim this study is to identify predictive in HCC patients.A total 41 patients with were enrolled retrospective study. Serum levels 22 circulating cytokines and angiogenic factors (CAFs) measured by multiplex Luminex assay. Profiles CAFs, clinical chemistry/hematology parameters, background...
Aim Combination therapy with sofosbuvir (SOF) plus velpatasvir (VEL) is approved for patients hepatitis C virus (HCV)‐related decompensated cirrhosis. We analyzed the real‐world efficacy of SOF/VEL therapy. Methods Thirty‐three HCV‐related cirrhosis (25 and eight Child B C, respectively) were treated 12 weeks. The HCV non‐structural protein (NS)5A NS5B drug resistance‐associated substitutions (RASs) determined by direct sequencing. Result Thirty‐two 33 completed treatment, but remaining...
The aim of this study is to compare the efficacy and safety hepatic arterial infusion chemotherapy (HAIC) between 5-fluorouracil (5-FU)-based continuous low-dose cisplatin (CDDP) monotherapy in patients with advanced hepatocellular carcinoma (HCC).Patients were grouped according HAIC regimen (5-FU group, n = 317/CDDP 66). A two-to-one match was created using propensity score analysis 102/CDDP 51). After matching, response rate (RR) adverse events as primary end-points, survival...
While the combination therapy of ribavirin (RBV) and sofosbuvir (SOF) is effective in genotype 2 HCV infection, predictors treatment efficacy posttreatment changes α‐fetoprotein (AFP) liver stiffness (markers hepatocellular carcinoma), remain unclear. In this study, 302 patients with chronic infection were treated SOF (400 mg) plus RBV (400‐1000 mg; based on body weight) for 12 weeks. We evaluated safety treatment, as well measured serum AFP, stiffness, controlled attenuation parameter (CAP,...
Transarterial chemoembolization (TACE) has been the standard treatment for intermediate-stage, unresectable hepatocellular carcinoma (u-HCC). However, with recent advances in systemic therapy and emergence of concept TACE-refractory or -unsuitable, effectiveness therapy, as well TACE, demonstrated patients judged to be -unsuitable. In this study, efficacy lenvatinib its combination TACE after was investigated 140 intermediate-stage u-HCC treated mainly because being Median overall survival...
Femoral fractures sometimes cause stiff knees. Most of them are treated with non-operative method, but there some cases we have to treat an operative method.Experienced ten knees were operated by Nicoll's, Kono's, Judet's and Thompson's methods. Preoperative R. O. M. 45 improved 95 in average postoperatively.
Non‑alcoholic steatohepatitis (NASH) may progress via liver fibrosis along with hepatic stellate cell (HSC) activation. A single nucleotide polymorphism (SNP; rs58542926) located in transmembrane 6 superfamily 2 (<em>TM6SF2</em>) has been reported to be significantly associated patients NASH, but the precise mechanism is still unknown. The present study aimed explore role of TM6SF2 HSC activation <em>in vitro</em>. Plasmids producing wild-type (WT) and mutant type (MT) containing...
Although direct-acting antivirals (DAAs) have significantly increased the sustained virological response (SVR) rates in chronic hepatitis C virus (HCV)-infected adult patients, efficacy and safety for children remain unclear. We herein report three HCV-infected who received DAA treatment. The patients were girls 10-13 years old had been infected with genotype 1b HCV by vertical transmission based on a phylogenetic tree analysis. Two treated 12 weeks of ombitasvir/paritaprevir/ritonavir,...
Having treated about 50 cases of fractures the Upper End Tibia from April, 1970 to March, 1978 in our hospital we'll report treatments and results 16 fractures, tibial spine 30 cases, plateau.It ensures satisfactory that we encourage patients muscle gymnastic femoral quadriceps as early possible after injuries order prevent atrophy adhesion patella, especially operated effort achive anatomical reduction firm fixation begin exercise immediately operation.
Objective Lusutrombopag is a thrombopoietin receptor agonist that improves thrombocytopenia in patients with chronic liver disease scheduled to undergo invasive procedures. However, information on the efficacy of repeated lusutrombopag treatment and factors associated scarce. We analyzed response lusutrombopag.
PURPOSE Postsustained virologic response (SVR) screening following clinical guidelines does not address individual risk of hepatocellular carcinoma (HCC). Our aim is to provide tailored for patients using machine learning predict HCC incidence after SVR. METHODS Using data from 1,028 SVR patients, we developed an prediction model a random survival forest (RSF). Model performance was assessed Harrel's c-index and validated in independent cohort 737 patients. Shapley additive explanation...